Akorn, Inc. (NASDAQ:AKRX) tinted gains of +7.8% (+1.39 points) to US$19.21. The volume of 7.05 Million shares climbed up over an trading activity of 3 Million shares. EPS ratio determined by looking at last 12 month figures is -0.97. Over the same time span, the stock marked US$33.73 as its best level and the lowest price reached was US$10.76. The corporation has a market cap of US$2.28 Billion.
Akorn, Inc. (NASDAQ:AKRX)’s earnings per share has been growing at a -26.9 percent rate over the past 5 year when average revenue increase was noted as 26.8 percent. The return on equity ratio or ROE stands at -11.1 percent while most common profitability ratio return on investment (ROI) was -0.6 percent. The company’s institutional ownership is monitored at 73.7 percent. The company’s net profit margin has achieved the current level of -12.2 percent and possesses 47.5 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 8 think it is Hold. Recently, analysts have updated the overall rating to 3. 0 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
aTyr Pharma, Inc. (NASDAQ:LIFE) is worth US$28.9 Million and has recently risen 7.78% to US$0.97. The latest exchange of 0.9 Million shares is below its average trading activity of 818.55 Million shares. The day began at US$0.91 but the price moved to US$0.87 at one point during the trading and finally capitulating to a session high of US$0.97. The stock tapped a 52-week high of US$6.5 while the mean 12-month price target for the shares is US$2.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0.53, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown -19.1%. With an institutional ownership near 71.3%, it carries an earnings per share ratio of -1.69.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 1 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 3.25.